HRT in 2026: Separating the Facts from the Fear

Few topics in women’s health generate as much confusion as hormone replacement therapy. Despite overwhelming evidence of its benefits when prescribed appropriately, many women remain unnecessarily fearful — often because of outdated information that has been comprehensively debunked by modern research. In my clinic, I spend a significant portion of every menopause consultation unpicking myths that patients have absorbed from headlines, social media, or well-meaning friends. So let me address the most persistent ones directly.

The WHI study: what actually happened

The primary source of HRT anxiety is the Women’s Health Initiative (WHI) study, published in 2002. The study suggested links between HRT and increased risks of breast cancer, heart disease, and stroke. The resulting media coverage was dramatic, and millions of women stopped HRT overnight. GPs pulled prescriptions. An entire generation of women was left to suffer menopausal symptoms without treatment.

What happened next is instructive: the original data was re-analysed, the study design was heavily critiqued, and subsequent research painted a far more nuanced picture. The WHI used conjugated equine oestrogen (derived from horse urine) combined with medroxyprogesterone acetate (a synthetic progestogen) — older formulations that are not what we prescribe today. The average age of participants was 63, and many were more than a decade past menopause. Some were smokers with pre-existing cardiovascular disease. This is a fundamentally different scenario from prescribing modern body-identical hormones to a symptomatic 48-year-old.

The WHI’s own follow-up data, published over the subsequent two decades, actually showed that women who started HRT closer to menopause had reduced cardiovascular mortality. The oestrogen-only arm of the study (for women without a uterus) showed a decreased risk of breast cancer. These findings barely made the news.

Myth by myth: the facts

Myth: HRT causes breast cancer.

The reality is more nuanced than a headline allows. Oestrogen-only HRT does not increase breast cancer risk — in fact, the WHI data showed a small reduction. Combined HRT (oestrogen plus a progestogen) does carry a small increased risk with prolonged use, but the magnitude is frequently overstated. The additional risk is comparable to that associated with drinking two glasses of wine per evening, being obese, or being physically inactive. Using body-identical micronised progesterone rather than older synthetic progestogens appears to carry a lower risk still. What I tell my patients is that this is a real but small risk that needs to be weighed against the very real benefits of treatment and the known health risks of untreated menopause, including osteoporosis and cardiovascular disease.

Myth: HRT is unnatural.

Body-identical hormones — 17-beta oestradiol and micronised progesterone — are molecularly identical to the hormones your ovaries produced for decades before menopause. They are derived from plant sources (yam) and are bioidentical in structure. Replacing a hormone that your body has stopped making is no more ‘unnatural’ than replacing thyroid hormone in hypothyroidism or insulin in diabetes. The framing of HRT as unnatural is a cultural bias, not a medical argument.

Myth: You should only take HRT for a few years.

This is one of the most damaging myths I encounter. There is no arbitrary time limit for HRT. The old advice to limit use to five years was based on the flawed WHI interpretation and has been superseded by current guidelines. NICE, the British Menopause Society, and the International Menopause Society all recommend an individualised approach — continuing HRT for as long as the benefits outweigh the risks, with regular review. Many of my patients take HRT well into their 60s and beyond, particularly for bone protection and quality of life. The decision to stop should be yours, made with your doctor, not dictated by an arbitrary deadline.

What does the current evidence say?

• Cardiovascular health: When started within 10 years of menopause (the ‘window of opportunity’), HRT is associated with reduced cardiovascular risk, not increased. Transdermal oestrogen in particular has an excellent cardiovascular safety profile.
• Breast cancer: The risk with combined HRT is small and must be contextualised. Body-identical progesterone carries a lower risk than synthetic progestogens. Oestrogen-only HRT shows no increased risk.
• Bone health: HRT is the most effective treatment for preventing osteoporotic fractures in postmenopausal women and is recommended as first-line therapy for osteoporosis prevention in women under 60.
• Brain health: Emerging evidence suggests that timely HRT may have protective effects against cognitive decline, although more research is needed.
• Quality of life: For women with significant menopausal symptoms, HRT can be transformative — improving sleep, mood, energy, sexual function, and overall wellbeing.

Routes of administration: why it matters

How you take HRT matters as much as whether you take it. I prescribe transdermal oestrogen (patches or gel applied to the skin) as my standard first-line approach, and here is why: oestrogen absorbed through the skin bypasses the liver entirely. This means it carries no increased risk of venous thromboembolism (blood clots) — unlike oral oestrogen tablets, which do carry a small VTE risk because they undergo first-pass liver metabolism. Transdermal oestrogen is safe for women with a higher BMI, women with migraines with aura, and women with a history of blood clots. It is also safe for smokers, though I naturally encourage smoking cessation.

For progesterone (required by any woman with a uterus, to protect the endometrium), I prescribe micronised progesterone (Utrogestan) — either taken orally at bedtime (where it has a helpful sedative effect that aids sleep) or, in some cases, via the Mirena IUS, which delivers progesterone directly to the uterus.

Who should and shouldn’t take HRT

HRT is appropriate for most women experiencing bothersome menopausal symptoms, particularly if they are under 60 or within 10 years of their last period. The absolute contraindications are few: current or recent hormone-receptor-positive breast cancer, active liver disease, undiagnosed vaginal bleeding, and active venous thromboembolism (though transdermal oestrogen may still be an option in some VTE scenarios after specialist assessment). A personal history of blood clots is not an automatic contraindication if transdermal oestrogen is used.

For the vast majority of symptomatic women, the benefits of HRT substantially outweigh the risks. The greater danger, in my clinical experience, is the harm done by not treating — years of poor sleep, low mood, fractured confidence, lost productivity, and accelerating bone loss.

Starting HRT: what to expect

I prepare my patients for the first three months, because this is the adjustment period. Some women feel dramatically better within days. Others take 8–12 weeks to notice the full benefit. During the settling-in phase, you may experience breast tenderness, mild bloating, or some irregular bleeding — all of which typically resolve as your body adjusts to stable hormone levels.

I usually see patients for a review at three months. At that point, we assess symptom response, check for any side effects, and adjust doses if needed. HRT is not a one-size-fits-all prescription — it often requires fine-tuning to get the formulation, dose, and route exactly right for you. That process is worth the patience. The women who come back to me at their three-month review and say they feel like themselves again — that is why I do this work.